Atropine Ointment
Atropine sulfate 1% · ophthalmic ointment
Mydriatics/Cycloplegics
Approved uses
Cycloplegic refraction
Small amount to the conjunctival sac once or twice a day.
Uncovers about 0.18 D more hyperopia than cyclopentolate 1%, with wide variation between individuals.
Pupillary dilation in inflammatory conditions of the iris and uveal tract
Small amount to the conjunctival sac once or twice a day.
OFF-LABELNot in the FDA label for this product
Myopia progression in children
1% ointment once daily for 1 year, the regimen used in the cited pilot.
Nonrandomized pilot · n=23
Nonrandomized pilot in 23 children aged 5 to 10 with myopia of -3.00 D or more, against 23 controls matched for age, sex, and baseline refraction: over 1 year myopic progression was +0.06 +/- 0.79 D versus -1.19 +/- 2.48 D (P = 0.005) and axial elongation 0.09 +/- 0.19 mm versus 0.70 +/- 0.63 mm (P = 0.004), with 1 allergic reaction among 23 treated. The authors concluded a large randomized trial with longer follow-up was still needed; the randomized evidence base for myopia control (ATOM2, LAMP) used low-concentration solutions, not this ointment.
Contraindications
- Primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma.
- Pediatric patients who have previously had a severe systemic reaction to atropine.
- Hypersensitivity to any component of this preparation.
Ophthalmic ointment, 1% (10 mg/g), 3.5 g ophthalmic tip applicator tube
Anticholinergic that blocks the response of the iris sphincter and of the ciliary body accommodative muscle to cholinergic stimulation. The result is pupillary dilation and paralysis of accommodation.
Warnings & Precautions
- Angle closure glaucoma: To avoid inducing angle closure glaucoma, estimate the depth of the angle of the anterior chamber before use.
- Systemic atropine poisoning: In pediatric patients use with extreme caution, and administration in infants requires great caution. Excessive use in pediatric patients or in certain individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic symptoms of atropine poisoning; if this occurs, discontinue medication and use appropriate therapy.
- Excessive systemic absorption: Compress the lacrimal sac by digital pressure for two to three minutes after instillation.
- Patient warning: Patients should not drive or engage in other hazardous activities while pupils are dilated, and should protect eyes in bright illumination because they may experience sensitivity to light. Parents should not get this preparation in their children's mouth and should wash their own hands and the child's hands after administration.
Common Side Effects
Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression, and coma and death have been reported in the very young. Systemic atropine toxicity is manifested by flushing and dryness of the skin (a rash may be present in pediatric patients), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, hallucinosis, and loss of neuromuscular coordination.
Pregnancy: No animal reproduction studies have been performed; whether fetal harm or an effect on reproductive capacity can occur is unknown, so use only if clearly needed.
Lactation: Not addressed on this label.
Extreme caution in children and infants; coma and death have been reported in the very young.